Abstract library

346 results for "serum protein".
#2783 Use of Plasma Proteins to Predict Progressive Disease in Patients with Small Intestinal Neuroendocrine Tumours
Introduction: Prediction of progression in small intestinal neuroendocrine tumors (SI-NET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD PhD Roger Belusa
#3003 The Proinflammatory Molecule, VAP-1, Is Enriched in the Stroma of Midgut NETs and Plaques of Carcinoid Heart Disease Valves
Introduction: Vascular adhesion protein-1 (VAP-1) is a novel driver of tissue inflammation and fibrosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Chris Weston
Authors: Shah T, Sagar V, Neil D, Liu B, ...
#16 Endoglin as indicator of metastatic neuroendocrine tumors of the pancreas
Introduction: Neuroendocrine tumors of the pancreas are rare, highly vascularized tumors. Endoglin, a Transforming Growth Factor-β co-receptor, is a marker for angiogenic endothelial cells. Angiogenesis is required for tumor progression and the development of metastases. Recently, endoglin expression was found to be a prognostic marker in pancreatic carcinomas. However, the role of endoglin in neuroendocrine pancreatic tumors has so far not been studied.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Patricia Kuiper
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#22 A Case Illustrative of Phenotypic Heterogeneity and Challenges in the Management of Paraganglioma
Introduction: Paragangliomas (PGLs) are extra-adrenal, usually benign, highly vascularized tumors that originate from neural-crest-derived chromaffin cells. These tumors are subdivided as either sympathetic or parasympathetic, depending on their location and catecholamine production. Sympathetic PGLs are situated along the abdominal sympathetic trunk and usually produce catecholamines, whereas parasympathetic PGLs are located in the head and neck, and these usually do not produce catecholamines. PGLs may present as sporadic or inherited tumor syndrome, including MEN 2, with RET germline mutations, von Hippel-Lindau (VHL) disease due to germline mutations in VHL gene, and pheochromocytoma-PGL syndrome. The latter is frequently a hereditary condition and is caused by germline mutations in the SDHB, SDHC, or SDHC genes. Patients with familial PGLs may present at a younger age, often as multifocal tumors, with an increased risk of recurrence and a higher frequency of malignancy in those with SDHB mutations. SDH mutations induce angiogenesis and tumorogenesis through the inhibition of hypoxia-inducible factors (HIF)-propyl hyroxylase. A younger age at onset, malignancy, and a positive family history are clinical parameters of high specificity, but low sensitivity for diagnosis. Genetic analysis for mutations in SDH genes for the patient and family members, and surveillance for the affected patient and family members, are necessary where there are no clear clinical or family indicators for the syndrome. We present a case of a large abdominal malignant PGL in a 20-year-old pt. that went on without clinical detection for at least three years.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohammed Ahmed
#189 Matrix metalloproteinases (MMPs) and Tissue Inhibitors of Matrix Metalloproteinases (TMIPs) in GEP NET Patients – A Potential Prognostic Biomarkers for Metastases
Introduction: MMPs have the ability to degrade the extracellular matrix and are responsible for tumor invasion and metastases. Higher TIMP-1 levels are associated with low survival rate in some types of cancer.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Jolanta Blicharz-Dorniak
#356 Activin A in Carcinoid Heart Disease: A Possible Role in Diagnosis and Pathogenesis
Introduction: Carcinoid heart disease (CHD), a complication of NETs, is characterized by right heart fibrotic lesions. In addition to serotonin, cytokines and growth factors with fibrogenic properties may play a role.
Conference:
Category: Basic
Presenting Author: MD, PhD Deidi S. Bergestuen
#415 Bevacizumab Plus Octreotide and Metronomic Capecitabine in Patients with Metastatic Well-to-Moderately Differentiated Neuroendocrine Tumors. The XELBEVOCT Multicenter Phase II Study
Introduction: A phase II study was designed to assess the activity and safety of metronomic oral capecitabine, bevacizumab, and octreotide (Xelbevoct) in metastatic well-to-moderately differentiated neuroendocrine neoplasms (WMD-NEN). We also assessed the predictive role for progression free survival (PFS) of hypertension, proteinuria and vascular endothelial growth factor (VEGF) polymorphisms and the predictive role of vitamin D on proteinuria and PFS.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Maria Pia Brizzi
Keywords: bevacizumab
#670 The Relationship Between the Ki-67 Protein and IGF-Related Genes in Gastroenteropancreatic Neuroendocrine Tumor Patients with Normal and Elevated Serum Chromogranin-A
Introduction: GEP-NETs are rare, heterogeneous neoplasms with a distinct biological and clinical behavior. Both IGF-system and Ki-67 indices have been reported as important stimulating factors in carcinogenesis and/or tumor progression. The tumor marker CgA is an independent predictor for survival as well. Currently no data are available about a possible interaction between IGF-system (IGF(-R)s, IRs, BPs) and Ki-67 protein in GEP-NET patients with normal and elevated serum CgA.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Drs Roxanne Van Adrichem
Keywords: GEP-NET
#674 Serum miRNA Expression in Small Intestine Neuroendocrine Tumors and Biological Function of miR-196a in Neuroendocrine Tumor Cells
Introduction: MicroRNAs (miRNAs), post-transcriptional regulators, function either as tumor suppressors or oncogenes. We recently identified five upregulated and four downregulated miRNAs in small intestinal neuroendocrine tumor (SI-NET) tissue. We then started new analysis on body fluids to detect tumor signatures using patients’ serum.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Rakan Naboulsi
Authors: Naboulsi R, Li S C, Cui T, Öberg K, ...